LENSAR, Inc. (NASDAQ:LNSR) Short Interest Update
by Teresa Graham · The Cerbat GemLENSAR, Inc. (NASDAQ:LNSR – Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,016,420 shares, an increase of 42.2% from the March 15th total of 714,594 shares. Based on an average daily volume of 321,629 shares, the days-to-cover ratio is presently 3.2 days. Approximately 24.7% of the company’s shares are sold short.
Institutional Trading of LENSAR
Several large investors have recently modified their holdings of the stock. Credit Industriel ET Commercial grew its position in shares of LENSAR by 0.8% during the 4th quarter. Credit Industriel ET Commercial now owns 124,483 shares of the company’s stock worth $1,448,000 after buying an additional 1,000 shares during the period. BNP Paribas Financial Markets increased its stake in LENSAR by 129.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock valued at $25,000 after purchasing an additional 1,131 shares in the last quarter. JPMorgan Chase & Co. increased its stake in LENSAR by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,928 shares of the company’s stock valued at $73,000 after purchasing an additional 1,254 shares in the last quarter. Barclays PLC increased its stake in LENSAR by 10.3% during the 4th quarter. Barclays PLC now owns 14,857 shares of the company’s stock valued at $173,000 after purchasing an additional 1,389 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in LENSAR by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 507,603 shares of the company’s stock valued at $6,269,000 after purchasing an additional 1,446 shares in the last quarter. Institutional investors and hedge funds own 40.15% of the company’s stock.
LENSAR Stock Performance
Shares of LNSR stock traded up $0.12 during trading hours on Tuesday, hitting $6.04. 92,665 shares of the company were exchanged, compared to its average volume of 221,575. The firm has a market cap of $73.08 million, a P/E ratio of -2.08 and a beta of 0.99. LENSAR has a fifty-two week low of $5.33 and a fifty-two week high of $14.31. The company has a 50 day simple moving average of $9.36 and a two-hundred day simple moving average of $10.80.
LENSAR (NASDAQ:LNSR – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The firm had revenue of $16.03 million for the quarter, compared to the consensus estimate of $20.30 million.
Wall Street Analyst Weigh In
Several research analysts have issued reports on LNSR shares. Lake Street Capital upgraded shares of LENSAR from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a report on Wednesday, April 1st. BTIG Research upgraded shares of LENSAR from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a report on Tuesday, March 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of LENSAR in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, LENSAR currently has an average rating of “Hold” and a consensus target price of $10.00.
Read Our Latest Analysis on LNSR
LENSAR Company Profile
LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.
Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.